In Regard to "A Phase Ib Study of NUC-1031 in Combination with Cisplatin for the First-Line Treatment of Patients with Advanced Biliary Tract Cancer (ABC-08)"

Abstract

This letter to the editor remarks on a recently published article on the use of NUC‐1031 and cisplatin for patients with biliary tract cancer and compares results of the landmark ABC‐02 trial.